Acalabrutinib (Calquence) — targeted therapy for CLL/SLL and selected B-cell lymphomas

What acalabrutinib is in simple patient language

Calquence — brand name. Acalabrutinib — the drug name in clinical records. Not chemo. Not immunotherapy. A targeted agent.

Comes as a capsule. Oral does not mean low risk. Labs, bleeding tendency, infections, heart rhythm — all of it gets checked throughout.

Why it comes up: some B-cell tumors rely on a particular internal signal to stay alive. Disease type, stage, prior treatment, blood values, bleeding history, heart rhythm, all current medications, and what this treatment needs to do — all of that gets reviewed before anything starts.

How acalabrutinib works

Inside certain tumor B-cells there is a protein called BTK. Without it, those cells cannot keep multiplying. Acalabrutinib goes after that protein directly. The survival signal gets cut.

Lymph nodes can shrink. Or the disease slows down without shrinking. Both outcomes can carry weight depending on the stage.

Bleeding tendency, infection history, cardiac rhythm, prior treatment — all of that shapes whether this approach fits right now.

Which diseases acalabrutinib may be used for

Not for every blood cancer. The doctor needs a defined clinical reason before it enters the plan.

• CLL — a slow-growing blood cancer affecting lymphocytes
• SLL — closely related to CLL, affects lymph nodes rather than blood
• mantle cell lymphoma in selected cases
• comparing BTK inhibitor options based on side effect profile and other health conditions
• disease that progressed after prior therapy
• first-line treatment where targeted therapy fits better than chemo
• second opinion when Calquence was proposed and the reasoning needs review

Same diagnosis, different patients — the plan can split at the first step. Prior drugs, organ function, disease pace, and treatment goal all shape the final decision.

When acalabrutinib can be especially relevant

Usually comes up when the doctor needs long-term disease control and the clinical picture points toward a BTK approach.

• B-cell disease where BTK signaling drives tumor activity
• prior therapy stopped working or became too difficult to tolerate
• Calquence needs to be compared with other drugs in the same class
• questions about bleeding risk, infections, headaches, or heart rhythm before starting
• managing treatment around other chronic medications

The goal matters more than the drug name. Hold the disease, replace a prior regimen, reduce symptoms, offer a workable long-term option — the doctor should be clear about which one applies here.

What needs to be checked before starting

One old record is not enough. The doctor needs a current picture of both the disease and the patient.

• biopsy report, immunohistochemistry, or flow cytometry
• molecular and cytogenetic results where available
• full prior treatment history — what was given, how long it held, why it stopped
• CBC — lymphocytes, neutrophils, platelets, hemoglobin
• liver and kidney markers
• infections, fever, fatigue, weight loss
• bruising, prior bleeding, anticoagulant or antiplatelet use
• palpitations, atrial fibrillation, or other cardiac issues
• blood pressure and full current medication list
• planned surgeries, dental work, or invasive procedures coming up

Sometimes the start gets delayed not because of the diagnosis but because of something else. Active infection, very low platelets, a rhythm problem, or a drug conflict gets addressed first.

How treatment with acalabrutinib goes

Capsule taken by mouth on the hematologist’s schedule. No self-adjusting doses. No stopping and restarting without checking first.

Treatment often runs for a long time. The doctor tracks not only lymph nodes and labs but also tolerability. Early headaches, bruising, and loose stool are common. Some settles on its own. Some needs checking.

What gets monitored regularly:

• CBC and lymphocyte trend
• platelets, neutrophils, hemoglobin
• liver and kidney values
• temperature and infection signs
• bruising, nosebleeds, blood in stool or urine
• blood pressure, palpitations, rhythm changes
• headache, fatigue, appetite, weight
• compatibility with new or existing medications

A side effect is not an automatic reason to stop. A pause, dose change, medication swap, or more frequent labs — those are all options. That call belongs to the doctor.

Possible side effects

Different patients, different problems. One person’s main complaint is headache. Another deals with bruising or infections. A third notices rhythm shifts.

What can appear:

• headache, tiredness, low energy
• loose stool, nausea, abdominal discomfort
• bruising, nosebleeds, heavier bleeding than usual
• neutrophils, platelets, or hemoglobin dropping
• upper respiratory or other infections
• skin rash, itching, dryness
• blood pressure going up
• palpitations, rhythm irregularities, arrhythmia
• rarely — more serious reactions needing separate evaluation

Small symptoms matter here. Unusual bruising, blood somewhere unexpected, fever, new breathlessness, heart rhythm shifts — none of these should be waited out.

When to contact a doctor urgently

Do not hold for the next scheduled appointment if any of these appear:

• fever, chills, worsening cough, or other infection signs
• bleeding, black stool, blood in urine, vomiting blood, unusual bruising
• severe headache, confusion, arm or leg weakness, speech or vision changes
• palpitations, chest pain, breathlessness, or fainting
• sudden severe fatigue or marked dizziness
• repeated diarrhea or trouble staying hydrated
• severe rash, face swelling, or breathing problems
• rapid decline without a clear reason

Whether the symptom seems related to the drug or not — that is the doctor’s call. Checking early beats missing something.

Why acalabrutinib is not right for everyone

Works well in the right situation. Not the right choice for every leukemia or lymphoma patient.

Reasons the doctor may go a different direction:

• disease biology does not support a BTK approach
• active severe infection
• platelets very low or significant bleeding recently
• medications that sharply raise bleeding risk or interact badly
• unstable arrhythmia or serious cardiovascular risk
• recent surgery or an invasive procedure coming up
• overall condition does not support safe long-term treatment
• a different approach fits the current goal better

A different choice is not a verdict on the drug. Sometimes another path fits the labs, the heart, or the treatment objective more cleanly.

Can acalabrutinib be combined with other treatments

Sometimes used alone. Sometimes part of a broader plan. Nothing gets added just to make a regimen heavier — each component needs a purpose.

• with antibodies or other systemic agents when that combination is part of the plan
• with supportive treatment for infections, low counts, fatigue, or other complaints
• with adjustment of existing medications where interactions are a concern
• with careful planning around surgeries or dental procedures

Blood thinners, antifungals, certain antibiotics, cardiac and blood pressure drugs — all need to be laid out in advance. A familiar medication can quietly change how safely treatment runs.

What no quick response to treatment can mean

Response looks different for different patients. Some notice changes early. For others things shift gradually and show up in labs, exam findings, and symptom trends.

At the start, blood count values can move in unexpected directions. That is not always a sign things are going wrong. The doctor reads lymph nodes, spleen, CBC, symptoms, and time on treatment together.

No visible early effect is not a reason to stop on your own. The doctor needs to figure out whether this is the normal pace of response, a tolerability issue, irregular dosing, a drug interaction, or a real reason to change direction.

Oncology consultation in Israel about acalabrutinib

At Tel Aviv Medical Clinic, patients with CLL/SLL, mantle cell lymphoma, or another B-cell condition can talk through whether acalabrutinib fits their specific situation.

A consultation may help to:

• understand why a BTK inhibitor is being proposed
• review which tests are needed before starting
• work through how to assess whether treatment is doing what it should
• get answers about bruising, infections, headache, heart rhythm, or planned surgery
• compare Calquence with other options in the same class
• prepare questions for the treating hematologist

We do not prescribe remotely and do not replace the treating physician. We help patients and families understand the logic behind the decision — and walk into the next step prepared.

Frequently asked questions — answered by Dr. Stefanska

1. Is acalabrutinib chemotherapy?

No. Works through BTK signaling in B-cells, not broad cytotoxic action. But not chemo does not mean no monitoring. Blood, infections, bleeding, cardiac rhythm — all of that still needs close regular attention. The capsule format changes nothing about that.

2. Why does the doctor choose Calquence and not something else?

The choice comes from the clinical task, not the brand. Disease type, stage, how fast things are moving, prior treatment, age, other health conditions, current medications — all of it feeds in. Calquence may look like a fit, but bleeding risk, infection history, arrhythmia, and how that specific patient tolerates treatment all factor into the final call.

3. Which tests are most important before starting?

Not just a blood count. I want the diagnosis confirmed — histology, immunohistochemistry, or flow cytometry. Molecular and cytogenetic data if done. Blood chemistry, liver and kidney markers. Platelet count and bleeding history. Infection status. Cardiac rhythm. Full medication list. Each one can shift the plan.

4. What should I do if bruising or bleeding appears?

Do not brush it off as fragile vessels. On a BTK inhibitor, those symptoms get reported. One small bruise with nothing else may not be urgent — but still gets noted. Blood in stool or urine, black stool, frequent nosebleeds, bad fatigue or dizziness — those cannot wait.

5. Why does the doctor ask about the heart and arrhythmia?

Cardiovascular risk needs to be understood before this therapy starts. Prior rhythm problems, atrial fibrillation, chest pain, breathlessness, or cardiac medications — all of it gets factored in. That does not always rule out Calquence, but it can change the monitoring approach and which regimen gets chosen.

6. Can surgery or a dental procedure be done during treatment?

Needs to be planned with the treating doctor ahead of time. Bleeding risk, platelet count, current medications, and urgency of the procedure all matter. Sometimes the drug is temporarily paused. Sometimes the preparation plan changes. Do not stop Calquence on your own before any procedure — that decision belongs to the doctor.

7. What documents should I bring to a consultation?

Discharge summaries. Confirmed diagnosis — histology or flow cytometry. Recent CBC and blood chemistry. Full prior treatment list with reasons for stopping. Current medication list. A short written timeline — when diagnosed, what was treated, what worked and how long, what side effects came up, and why acalabrutinib is being discussed now. That history shows clinical logic, not just a name on a form.

Important information

General medical information only. Not a treatment recommendation. Acalabrutinib is considered only after full review of the diagnosis, test results, prior therapy, blood counts, bleeding risk, infections, cardiac factors, and overall patient condition.

Do not start, stop, or change any treatment without speaking with your treating physician first.

Contacts

To arrange a consultation about acalabrutinib:

📞 +972-73-374-6844

📧 [email protected]

💬 WhatsApp: +972-52-337-3108